Outcomes and Control Rates for I-125 Plaque Brachytherapy for Uveal Melanoma: A Community-Based Institutional Experience

Table 5

Analysis of factors predicting for treatment side effects.

	Absent (mean)	Present (mean)	𝑃 value
Cataracts
Lens dose (Gy)	14.67	24.64	0.05
Glaucoma
Lens dose (Gy)	17.12	32.11	0.04
Retinopathy
5 mm depth dose (Gy)	78.48	108.6	0.01
Inner dclera dose (Gy)	280.65	333	0.14
Tumor size (mm)	10.47	10.52	0.93
Tumor height (mm)	4.26	4.68	0.40
Dose apex (Gy)	91.19	96.99	0.04
Optic neuropathy
Macula dose	62.51	95.7	0.22
Optic disk dose	47.06	48.83	0.93
Clinically useful vision
Tumor size (mm)	11.22	10.28	0.10
5 mm depth dose (Gy)	98.34	83.48	0.15
Optic disk dose (Gy)	55.25	44.81	0.25
Inner sclera dose (Gy)	343.67	280.75	0.10
Macula dose (Gy)	75.49	60.31	0.20